Number of pages: 100 | Report Format: PDF | Published date: 20 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Growth Rate |
CAGR of 4.26% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Historical Year |
2020 |
Segments covered |
Treatment Type, End User, and Region |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global keratosis pilaris treatment market is expected to register a revenue CAGR of 4.26% during the forecast period.
Market Fundamentals
Keratosis pilaris or chicken skin is the most prevalent and non-contagious skin condition. The disorder results in tiny, painful lumps which damage the texture of the skin. The bumps frequently have a pale complexion. They commonly occur on the upper arms, thighs, and buttocks, and may be accompanied by redness or swelling. Keratosis pilaris is caused by the accumulation of keratin, a protein that defends the skin from infections and other hazardous substances. The buildup creates a block that prevents hair follicles.
Even though keratosis pilaris is a frequent condition, its specific cause is still unknown. The disorder is inherited in an autosomal dominant manner. Filaggrin mutations have been linked to keratosis pilaris as well as abnormalities in the RAS signaling cascade. Mutations in the filaggrin gene may cause follicular abnormalities. This link, along with mutations in the filaggrin gene, shows that keratosis pilaris is caused by a lack of normal epithelial barrier function. Moreover, recent studies have suggested a link between vitamin A deficiency. People with vitamin A deficiency can develop keratosis pilaris more frequently. Additionally, people with asthma, hypothyroidism, diabetes, and obesity are also prevalent to develop the disease due to hormonal imbalance. This disease is very common in adolescent age group. When teenagers come into their late adolescence, the bumps can disappear. Hormonal imbalance, on the other hand, can trigger another flare-up around puberty. Keratosis pilaris usually clears by the mid-20s if it begins during adolescence.
Market Dynamics
The increasing prevalence of keratosis pilaris is the key factor driving the global keratosis treatment market. This condition is more prone in children and young adults due to changes in hormones. According to the estimates of the British Association of Dermatologists in 2021 about 50% of people have keratosis pilaris (KP). About 40% of adults and 50% to 70% of teenagers are affected by it.
Advancement in treatment for keratosis pilaris is another factor driving the global keratosis treatment market. For instance, chlorine dioxide is a powerful antibacterial and anti-inflammatory agent that is non-toxic to humans. This is highly used in keratosis pilaris which inactivates the intracellular defense system, with no side effects. Chlorine dioxide is an excellent cleaning agent. Furthermore, it acts as a keratolytic agent by neutralizing reactive oxygen molecules and breaking the intramolecular and intermolecular disulfide bonds that hold keratin together.
Social hesitation among adults plays a significant role in increasing the growth of the keratosis pilaris treatment market. Many people with keratosis pilaris feel self-conscious about the appearance of their skin, especially in social situations. As more people are seek solutions to manage the condition, the market for keratosis pilaris treatments is likely to grow in the forecast period.
Market Ecosystem
The global keratosis pilaris treatment market has been analyzed from four perspectives: Treatment Type, End User, and Region.
Keratosis Pilaris Treatment Market by Treatment Type
[4534234]
Based on treatment type the global keratosis pilaris treatment market is segmented into topical exfoliants, topical retinoids, and others. Topical exfoliants are currently leading the global ketosis pilaris treatment market in terms of revenue. The topical exfoliants segment is further sub-segmented into lotions, creams, and others. Topical exfoliants have significant advantages in treating keratosis pilaris. Exfoliants are essential in removing small keratin lumps covering follicles. Moreover, topical exfoliants focus on removing dead skin and reducing hair follicles. Moreover, topical exfoliants are advantageous since keratosis pilaris typically goes away in the 30s. Lotions containing alpha hydroxy acid, lactic acid, salicylic acid, and urea aid in removing dead skin cells and are primary exfoliants prescribed by the doctor. Topical retinoids are creams that are derived from vitamin A, they function by accelerating cell renewal and avoiding clogged hair follicles. Topical retinoids include medications like tazarotene (Arazlo, Avage, Tazorac, and others) and tretinoin (Avita, Renova, Retin-A, and others) which improves the texture of the skin. The exfoliating properties of vitamin A derivative also promote the growth of new skin cells, resulting in the smoothing of chicken skin bumps. Several laser treatments, including 532nm potassium-titanyl-phosphate (KTP) laser, 595nm pulsed-dye laser (PDL), long-pulsed 1,064nm neodymium-doped yttrium aluminum garnet (Nd: YAG) laser, Q-switched 1,064nm Nd: YAG laser, 810nm diode laser, and fractional carbon dioxide laser are effective for treating keratosis pilaris. Moreover, the treatment can certainly reduce rough skin texture and uneven skin tone.
Keratosis Pilaris Treatment Market by End User
Based on the end-user the global keratosis pilaris treatment market is grouped into hospitals, dermatology clinics, home care settings, and others.
Hospitals provide better treatment for keratosis pilaris, and dominate the global keratosis pilaris treatment market. This is due to their access to more specialized equipment and personnel than other care providers. Additionally, they offer access to more advanced specialists, including dermatologists and plastic surgeons, who can treat the condition with greater efficacy. hospitals have a greater ability to monitor and track progress, ensuring that patients are receiving the best possible care. Furthermore, hospitals have access to more advanced treatment options such as laser treatment.
Keratosis Pilaris Treatment Market by Region
Regionally, the global keratosis pilaris treatment market has been segmented into North America, Europe, Asia Pacific, and the rest of the world
North America dominated the market with the highest market share in 2021. The market in the region is anticipated to be driven by an increase in awareness of keratosis pilaris, a high rate of treatment adoption due to an increase in physician prescriptions, and developments in laser therapy in the U.S. During the projection period, the segment is expected to be driven by favorable regulatory policies, an increase in the number of keratosis pilaris sales made through online pharmacies, and a rise in the amount of private players' spending for R&D. Asia Pacific is likely to grow at hogh CAGR during the forecast period. Some of the major drivers propelling the global keratosis pilaris treatment market throughout the projection period include an increase in treatment adoption, growing disposable income among consumers, and high disease prevalence in some countries, such as India, Australia and New Zealand.
Competitive Landscape
The prominent players operating in the global keratosis pilaris treatment market are.
Strategic Developments
In April 2022, Almirall S.A. collaborated with the University of Dundee to develop novel approaches to treat dermatological disorders where itching and pruritus plays a dominant role. This collaboration is aimed in building a proprietary immune-based treatment for chronic inflammatory conditions. The major goal of this partnership is to fully control the itch associated with skin conditions and attain a prolonged and deep therapeutic effect for patients. Itch represents one of the most bothersome symptoms in several dermatological diseases and has a huge impact on patients’ quality of life. The advantage of this new approach over current treatments using the administration of therapeutic antibodies will be the lower frequency of dosing while achieving a deeper therapeutic effect.
The global keratosis pilaris treatment market is currently driven by the increased increasing awareness about actinic keratosis, knowledge about diagnostics and treatment strategies, and various strategic initiatives undertaken by industry players.
Some of the prominent players operating in the global keratosis pilaris treatment market are Neostrata Company, Inc., Procter & Gamble Company, and SLMD Skincare. Johnson & Johnson Pvt. Ltd., Galderma S.A., Touch Skin Care, Novartis AG, L’Oreal S.A. Summit Medical Group, and Sun Pharmaceutical Industries Ltd.
Complications after keratosis treatment can hamper the global keratosis pilaris treatment market to some extent.
The global keratosis pilaris treatment market is expected to witness a CAGR of 4.26 % during the forecast period from 2022 to 2030.
Based on treatment type, the global keratosis pilaris treatment market is segmented into topical exfoliants, topical retinoids, and others. The topical exfoliants segment helds majority of the revenue share in 2021.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.